J2779 Injection, susvimo 0.1 milligrams
J-Codes
Also known as: susvimo, ranibizumab sustained-release
Injection of ranibizumab (Susvimo sustained-release implant formulation), 0.1 milligrams, for extended intravitreal delivery to retinal tissues.
Clinical Context
Used as a sustained-release intravitreal implant for age-related macular degeneration (AMD) requiring long-term anti-VEGF therapy.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.